CN101443333A - 用于治疗癌症和其它病症的雷帕霉素的36-去(3-甲氧基-4-羟基环已基)-36-(3-羟基环庚基)衍生物 - Google Patents

用于治疗癌症和其它病症的雷帕霉素的36-去(3-甲氧基-4-羟基环已基)-36-(3-羟基环庚基)衍生物 Download PDF

Info

Publication number
CN101443333A
CN101443333A CNA2007800177480A CN200780017748A CN101443333A CN 101443333 A CN101443333 A CN 101443333A CN A2007800177480 A CNA2007800177480 A CN A2007800177480A CN 200780017748 A CN200780017748 A CN 200780017748A CN 101443333 A CN101443333 A CN 101443333A
Authority
CN
China
Prior art keywords
compound
expression
arbitrary
rapamycin
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800177480A
Other languages
English (en)
Chinese (zh)
Inventor
巴里·威尔金森
明强·张
罗丝·玛丽·谢里登
克里斯托夫·贝克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotica Technology Ltd
Original Assignee
Biotica Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Technology Ltd filed Critical Biotica Technology Ltd
Publication of CN101443333A publication Critical patent/CN101443333A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800177480A 2006-05-19 2007-05-18 用于治疗癌症和其它病症的雷帕霉素的36-去(3-甲氧基-4-羟基环已基)-36-(3-羟基环庚基)衍生物 Pending CN101443333A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0609962.6 2006-05-19
GBGB0609962.6A GB0609962D0 (en) 2006-05-19 2006-05-19 Novel compounds

Publications (1)

Publication Number Publication Date
CN101443333A true CN101443333A (zh) 2009-05-27

Family

ID=36660469

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800177480A Pending CN101443333A (zh) 2006-05-19 2007-05-18 用于治疗癌症和其它病症的雷帕霉素的36-去(3-甲氧基-4-羟基环已基)-36-(3-羟基环庚基)衍生物

Country Status (10)

Country Link
US (1) US20090209572A1 (https=)
EP (1) EP2027130A1 (https=)
JP (1) JP2009537502A (https=)
CN (1) CN101443333A (https=)
AU (1) AU2007253118A1 (https=)
BR (1) BRPI0711945A2 (https=)
CA (1) CA2651405A1 (https=)
GB (1) GB0609962D0 (https=)
MX (1) MX2008014746A (https=)
WO (1) WO2007135397A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102268015A (zh) * 2011-08-30 2011-12-07 成都摩尔生物医药有限公司 一种依维莫司的合成方法
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
CN106916835A (zh) * 2015-12-24 2017-07-04 武汉臻智生物科技有限公司 化合物的生物合成基因簇及其应用
CN107530298A (zh) * 2015-01-26 2018-01-02 耶鲁大学 利用酪氨酸激酶抑制剂的组合物和方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601201B1 (en) 2010-08-04 2014-09-24 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
EP2670756B1 (en) * 2011-02-04 2017-06-21 Synthon BV Process for making everolimus
EP3109250A1 (en) 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5912253A (en) * 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
CA2492153C (en) * 2002-07-16 2012-05-08 Biotica Technology Limited Production of polyketide fkbp-ligand analogues

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102268015A (zh) * 2011-08-30 2011-12-07 成都摩尔生物医药有限公司 一种依维莫司的合成方法
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
CN107530298A (zh) * 2015-01-26 2018-01-02 耶鲁大学 利用酪氨酸激酶抑制剂的组合物和方法
CN106916835A (zh) * 2015-12-24 2017-07-04 武汉臻智生物科技有限公司 化合物的生物合成基因簇及其应用
CN106916835B (zh) * 2015-12-24 2022-08-12 武汉合生科技有限公司 化合物的生物合成基因簇及其应用

Also Published As

Publication number Publication date
US20090209572A1 (en) 2009-08-20
BRPI0711945A2 (pt) 2011-12-13
EP2027130A1 (en) 2009-02-25
CA2651405A1 (en) 2007-11-29
WO2007135397A1 (en) 2007-11-29
JP2009537502A (ja) 2009-10-29
MX2008014746A (es) 2009-02-19
GB0609962D0 (en) 2006-06-28
AU2007253118A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US7648996B2 (en) 39-desmethoxy derivatives of rapamycin
EP2471797B1 (en) 17-desmethylrapamycin and analogues thereof, methods for their production and their use as immunosupressants, anticancer agents, antifungal agents etc.
HUT73418A (en) Process for preparing rapamycin carbonate esters and pharmaceutical compositions of immunosuppressive activity containing said compounds
US20090209572A1 (en) 36-Des(3-Methoxy-4-Hydroxycyclohexyl) 36-(3-Hydroxycycloheptyl) Derivatives of Rapamycin for the Treatment of Cancer and Other Disorders
US7897608B2 (en) 39-desmethoxy-39-methyl derivatives of rapamycin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090527